Myeloid cell factor-1 is a critical survival factor for multiple myeloma

Blood

Volumn 99, Issue 6, 2002, Pages 1885-1893

  Zhang, Bin ^a   Gojo, Ivana ^a   Fenton, Robert G ^a,b  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CASPASE; DACTINOMYCIN; GENE PRODUCT; INTERLEUKIN 6; MYELOID CELL FACTOR 1; PROTEASOME INHIBITOR; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN FAMILY;

EID: 0037085778     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.1885     Document Type: Article

References (86)

1. Prognostic factors in multiple myeloma
2. Multiple myeloma: Increasing evidence for a multistep transformation process
3. Autotransplants in multiple myeloma: Pushing the envelope
4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
5. The role of adhesion receptors in the pathogenesis of multiple myeloma
6. Multiple myeloma cell adhesion-induced interieukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
7. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance
8. Monoclonal gammopathy of undetermined significance: Chromosome changes are a common finding within bone marrow plasma cells
9. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma
10. Cytogenetic abnormalities in multiple myeloma
11. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
12. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias
13. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6
14. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
15. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or inteleukin 6-mediated up-regulation of bcl-xL
16. Interleukin-6 inhibits apoptosis of malignant plasma cells
17. Inteleukin-6 prevents dexamethasone-induced myeloma cell death
18. Mechanisms of myeloma cell growth control
19. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
20. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
21. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6
22. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
23. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway
24. BCL-2 family members and the mitochondria in apoptosis
25. Bcl-2 family proteins
26. The Bcl-2 protein family: Arbiters of cell survival
27. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy
28. Bcl-2 protein expression is not related to short survival in multiple myeloma
29. Bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: A comparative study
30. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells
31. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance
32. In vivo localisation and stability of human Mcl-1 using green fluorescent protein (GFP) fusion proteins
33. PEST sequences and regulation by proteolysis
34. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2
35. Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells
36. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
37. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
38. The transcriptional elongation inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase
39. Mechanism of action of dichlorobeta-D-ribofuranosylbenzimidazole: Effect on in vitro transcription
40. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis
41. Protein kinase inhibitors flavopiridol and 7-hydroxystaurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
42. Mechanisms of action of flavopiridol
43. Preclinical and clinical development of cyclin-dependent kinase modulators
44. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase
45. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
46. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo
47. Reversible phosphorylation of the C-terminal domain of RNA polymerase II
48. Inhibitors of transcription such as 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole and isoquinoline sulfonamide derivatives (H-8 and H-7) promote dephosphorylation of the carboxyl-terminal domain of RNA polymerase II largest subunit
49. From bench to clinic with apoptosis-based therapeutic agents
50. Mcl-1 expression in human neutrophils: Regulation by cytokines and correlation with cell survival
51. Induction of apoptosis (programmed cell death) in human leukemic HL-60 cells by inhibition of RNA or protein synthesis
52. Rapid apoptotic cell death of B-cell hybridomas in absence of gene expression
53. Proliferation, cell cycle and apoptosis in cancer
54. Bone marrow angiogenesis and progression in multiple myeloma
55. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma
56. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
57. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells
58. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo
59. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes
60. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2
61. Protection from cell death by mcl-1 is mediated by membrane hyperpolarization induced by K(+) channel activation
62. Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: Evidence for a novel mechanism of regulating Bcl-2 family protein function
63. Interactions among members of the Bcl-2 protein family analyzed with a yeast two-hybrid system
64. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions
65. Mcl-1 is an immediate-early gene activated by the granulocytemacrophage colony-stimulating factor (GM-CSF) signaling pathway and is one component of the GM-CSF viability response
66. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C
67. Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation
68. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB
69. BCL-2 and MCL-1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine
70. Mcl-1 deficiency results in periimplantation embryonic lethality
71. Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice
72. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice
73. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes
74. Signaling: 2000 and beyond
75. Genetic instabilities in human cancers
76. Disruption of epithelial cell-matrix interactions induces apoptosis
77. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
78. The hallmarks of cancer
79. Regulation of p53 function
80. The inhibitors of apoptosis (IAPs) and their emerging role in cancer
81. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
82. PTEN: A tumour suppressor that functions as a phospholipid phosphatase
83. Cellular survival: A play in three Akts
84. p53 and RAS gene mutations in multiple myeloma
85. Loss of PTEN expression leading to high Akt activation in human multiple myelomas
86. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo